Erratum: The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.

Cheng-Wei Chou, Ri-Yao Yang, Li-Chuan Chan, Ching-Fei Li, Linlin Sun, Heng-Huan Lee, Pei-Chih Lee, Yuh-Pyng Sher, Haoqiang Ying, Mien-Chie Hung

Abstract readPublished Erratum

PubMed Full text at PMC

In one paragraph

Article in American journal of cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity.International journal of biological sciences · 2023
Article

4 · The record

Corrections and comments

Erratum for
The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.2020

5 · Who and what money

Authors and funding

10 authors.

Cheng-Wei ChouGraduate Institute of Biomedical Sciences, China Medical University Taichung 404, Taiwan.

Ri-Yao YangDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA.

Li-Chuan ChanDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA.

Ching-Fei LiDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA.

Linlin SunTianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital Tianjin 30052, P. R. China.

Heng-Huan LeeDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA.

Pei-Chih LeeGraduate Institute of Biomedical Sciences, China Medical University Taichung 404, Taiwan.

Yuh-Pyng SherGraduate Institute of Biomedical Sciences, China Medical University Taichung 404, Taiwan.

Haoqiang YingDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA.

Mien-Chie HungGraduate Institute of Biomedical Sciences, China Medical University Taichung 404, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article on p. 2621 in vol. 10, PMID: 32905506.].

Identifiers

PMID33163286

PMCPMC7642660

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.